A Randomized Phase II Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Non-squamous Non-small Cell Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
predictive value of TS expression
To determine the predictive value of thymidylate synthase expression in NSCLC patients treated with pemetrexed combination therapy by interaction P value
12 months
No
Myung-Ju Ahn, M.D., Ph.D.
Principal Investigator
Samsung Medical Center
Korea: Food and Drug Administration
2011-06-006
NCT01401192
July 2011
Name | Location |
---|